Organovo Holdings, Inc. (LON: 0R02)
London
· Delayed Price · Currency is GBP · Price in USD
0.363
-0.017 (-4.40%)
Jan 22, 2025, 3:53 PM BST
Organovo Holdings Revenue
Organovo Holdings had revenue of $30.00K USD in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $103.00K, down -72.01% year-over-year. In the fiscal year ending March 31, 2024, Organovo Holdings had annual revenue of $109.00K, down -70.54%.
Revenue (ttm)
$103.00K
Revenue Growth
-72.01%
P/S Ratio
n/a
Revenue / Employee
$5.15K
Employees
20
Market Cap
4.46M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Organovo Holdings News
- 16 days ago - Organovo appoints Norman Staskey as CFO - Seeking Alpha
- 17 days ago - Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - GlobeNewsWire
- 2 months ago - Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - GlobeNewsWire
- 6 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 6 months ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 8 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 9 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire